Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1557414 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Fluoroscopy-free cardioneuroablation for functional bradycardia: a single-center experience.
J Interv Card Electrophysiol
October 2024
Department of Pediatric Cardiology, Akron Children's Hospital, Akron, OH, USA.
Article Synopsis
- The study investigates the safety and effectiveness of a fluoroless Cardioneuroablation (CNA) approach in treating cardiac issues like syncope and AV block among 22 young patients (average age 21).
- The procedure successfully eliminated or reduced the vagal response in all patients, with an average operation time of 251 minutes and fluoroscopy avoided in 91% of cases.
- At follow-up (around 11.4 months later), 77% of patients were symptom-free, with 90% of those needing pacemakers not requiring further pacing, indicating a promising outcome without complications.
Dual-chamber pacing with closed-loop stimulation in a sleep syncope case.
HeartRhythm Case Rep
September 2024
Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Cardioneuroablation for the treatment of reflex syncope and functional bradyarrhythmias: A Scientific Statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS) and the Latin American Heart Rhythm Society (LAHRS).
Europace
August 2024
Department of Cardiology, HCor Hospital do Coracao, Sao Paulo, SP, Brasil.
Cardioneuroablation has emerged as a potential alternative to cardiac pacing in selected cases with vasovagal reflex syncope, extrinsic vagally induced sinus bradycardia-arrest or atrioventricular block. The technique was first introduced decades ago, and its use has risen over the past decade. However, as with any intervention, proper patient selection and technique are a prerequisite for a safe and effective use of cardioneuroablation therapy.
View Article and Find Full Text PDFBackground: Neurocardiogenic syncope is a common condition with significant associated psychological and physical morbidity. The effectiveness of therapeutic options for neurocardiogenic syncope beyond placebo remains uncertain.
Methods: The primary endpoint was the risk ratio (RR) of spontaneously recurring syncope following any therapeutic intervention.
Making certain that noninvasive therapy for vasovagal syncope has failed before proceeding to invasive interventions.
Europace
March 2024
Department of Cardiology, National Heart & Lung Institute, Hammersmith Hospital Campus, Du Cane Road, London W12 0HS, UK.
There is a perceived need to express concisely the advice of guidelines in the context of consideration of invasive management of highly symptomatic vasovagal syncope. In response to this need the table is presented as a checklist and the text adds explanation and details. It is anticipated that this will prove to be of value for clinicians.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!